Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms – outcome from a randomized controlled trial
Tóm tắt
Controversy remains on the superiority of combination therapy over monotherapy on ureteral stent-related symptoms (SRSs). We tend to explore if there is a necessity of combination therapy. One hundred cases of unilateral upper urinary tract calculi with stent insertion (pre and post flexible ureteroscopy) were randomized into 4 groups, given non-treatment, solifenacin, tamsulosin or combination respectively. Eight times of follow-ups were given after each insertion. SRSs released spontaneously within 4 days after insertion (p = 0.017) but then stay with no further improvement. Benefit of solifenacin on flank pain started showing after day4 (p = 0.002), which was comparable to that of tamsulosin and combination (p = 0.914 vs 0.195). Combination therapy showed superiority over both monotherapy before day4, but after then solifenacin and tamsulosin showed similar effectiveness with the combination therapy on both bladder pain (p = 0.229 vs 0.394) and urgency (p = 0.813 vs 0.974). No improvement on hematuria or frequency was observed in each group. Combination therapy takes effect faster but shows no supervisory after the first few days compared with monotherapy. The study protocol was registered on Chinese Clinical Trial Register on April 17th, 2013 (registration number:
ChiCTR-TRC-13003148
).
Tài liệu tham khảo
Joshi HB, Okeke A, Newns N, et al. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59(4):511–6.
Bosio A, Dalmasso E, Destefanis P, et al. How bothersome ureteral stents are after ureteroscopy? A prospective study using a validated questionnaire(USSQ). Eur Urol Suppl. 2005;14(2):e1075.
Ritter M, Krombach P, Knoll T, et al. Initial experience with a newly developed antirefluxive ureter stent. Urol Res. 2012;40(4):349–53.
Dellis A, Joshi HB, Timoney AG, et al. Relief of stent related symptoms: Review of engineering and pharmacological solutions. J Urol. 2010;184(4):1267–72.
Lange D, Bidnur S, Hoag N, et al. Ureteral stent-associated complications - where we are and where we are going. Nat Rev Urol. 2015;12(1):17–25.
Walker NAF, Bultitude MF, Brislane K, et al. Management of stent symptoms: what a pain! BJU Int. 2014;114(6):797–8.
Zhou L, Cai X, Li H, et al. Effects of α-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol. 2015;29(6):650–6.
Jinsung P, Changhee Y, Deok HH, et al. A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent- related symptoms: a 2 × 2 factorial randomized trial. World J Urol. 2015;33(11):1833–40.
EL-Nahas AR, Tharwat M, Elsaadany M, et al. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent related symptoms. Eur Urol Suppl. 2015;14(2):e1076–e1076a.
Lee SJ, Yoo C, Oh CY, et al. Stent position is more important than α-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: a prospective randomized study. Korean J Urol. 2010;51(9):636–41.
Giannarini G, Keeley Jr FX, Valent F, et al. Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated Ureteric Stent Symptoms Questionnaire. BJU Int. 2011;107(4):648–54.
Irani J, Siquier J, Pires C, et al. Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int. 1999;84:276–9.
Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. Urol Int. 2009;83(1):66–9.
Tehranchi A, Rezaei Y, Khalkhali H, et al. Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol. 2013;39(6):832–40.
Beddingfield R, Pedro RN, Hinck B, et al. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol. 2009;181:170–6.
Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3:46–53.
Yamaguchi O. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol. 2013;20(1):28–39.
Shalaby E, Ahmed AF, Maarouf A, et al. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms. Adv Urol. 2013;2013:752382.
Lim KT, Kim YT, Lee TY, et al. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol. 2011;52(7):485–8.